142 related articles for article (PubMed ID: 30582868)
1. EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION6ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF-ASSESSMENT MPN-SAF TSS.
Shumeiko OO; Poluben LO; Klimuk BT; Rybchenko LA; Neumerzhitskaya LV; Verbilenko RM; Frolov SV; Klymenko SV
Probl Radiac Med Radiobiol; 2018 Dec; 23():510-516. PubMed ID: 30582868
[TBL] [Abstract][Full Text] [Related]
2. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
[TBL] [Abstract][Full Text] [Related]
3. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
[TBL] [Abstract][Full Text] [Related]
4. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
[TBL] [Abstract][Full Text] [Related]
6. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA
J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245
[TBL] [Abstract][Full Text] [Related]
8. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
9. [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].
Xu J; Xu Z; Wang J; Li B; Sun X; Qin T; Zhang Y; Zhang H; Fang L; Pan L; Hu N; Qu S; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):26-9. PubMed ID: 26876249
[TBL] [Abstract][Full Text] [Related]
10. Genetic complexity of myeloproliferative neoplasms.
Kralovics R
Leukemia; 2008 Oct; 22(10):1841-8. PubMed ID: 18754034
[TBL] [Abstract][Full Text] [Related]
11. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
12. Aberrant signal transduction pathways in myeloproliferative neoplasms.
Kota J; Caceres N; Constantinescu SN
Leukemia; 2008 Oct; 22(10):1828-40. PubMed ID: 18769448
[TBL] [Abstract][Full Text] [Related]
13. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
17. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
18. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST; Gotlib J
Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
[TBL] [Abstract][Full Text] [Related]
20. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
